Drugs / IGNX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06331728 | Sep 2024 → Nov 2025 | food allergy | IgGenix Australia Pty Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGNX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06331728 ↗ |
| Route | Subcutaneous | “IGNX001 given as a single subcutaneous dose on Day 1.” NCT06331728 ↗ |